|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/495 | |
| A61P 9/10 | |||
| G01N 33/68 | |||
| A61K 9/08 | |||
| A61K 9/22 |
| (11) | Number of the document | 2170333 |
| (13) | Kind of document | T |
| (96) | European patent application number | 08732776.3 |
| Date of filing the European patent application | 2008-03-24 | |
| (97) | Date of publication of the European application | 2010-04-07 |
| (45) | Date of publication and mention of the grant of the patent | 2013-02-20 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2008/058063 |
| Date | 2008-03-24 |
| (87) | Number | WO 2008/150565 |
| Date | 2008-12-11 |
| (30) | Number | Date | Country code |
| 941210 P | 2007-05-31 | US |
| (72) |
BLACKBURN, Brent, US
JERLING, Marcus, SE
WOLFF, Andrew, US
|
| (73) |
Gilead Sciences, Inc.,
333 Lakeside Drive, Foster City, CA 94404,
US
|
| (54) | RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE |
| RANOLAZINE FOR ELEVATED BRAIN-TYPE NATRIURETIC PEPTIDE |